265 results on '"Hermans, Cedric"'
Search Results
2. Targeted treatments for vascular malformations: current state of the art
3. Proactive systematic hemophilia carrier screening: a step toward gender equity in hemophilia care
4. The association between unemployment and treatment among adults with hemophilia
5. Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind
6. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
7. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
8. The underevaluated impacts of the therapeutic revolution of hemophilia on women and girls
9. Direct oral anticoagulants and venous malformations: literature review and retrospective study of 29 patients
10. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
11. The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients
12. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis
13. Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
14. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
15. Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast
16. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective
17. Haemophilia gene therapy: experiences and lessons from treated patients
18. A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results.
19. Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone.
20. The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study
21. Emicizumab as first line therapy in acquired hemophilia A
22. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A
23. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
24. Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding
25. Optimising prophylaxis in haemophilia A: The ups and downs of treatment
26. Average Nucleotide Identity and Digital DNA-DNA Hybridization Analysis Following PromethION Nanopore-Based Whole Genome Sequencing Allows for Accurate Prokaryotic Typing.
27. Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries
28. Reliability and construct validity of the ACTIVLIM‐Hemo and Haemophilia Activities List (HAL) questionnaires in individuals with haemophilia
29. The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study
30. The impact of emicizumab on the clinical validation of new therapies for haemophilia A.
31. Impact of uORFs in mediating regulation of translation in stress conditions
32. Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List
33. The value‐based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia.
34. The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients
35. Joint status, pain and quality of life in elderly people with haemophilia: A case‐control study
36. New insights into the diagnosis and management of patients with type 2M von Willebrand disease
37. Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic cell transplantation.
38. Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List
39. MariClus: Your One-Stop Platform for Information on Marine Natural Products, Their Gene Clusters and Producing Organisms
40. The 2023 Belgian clinical guidance on anticoagulation management in hospitalized and ambulatory COVID-19 patients
41. Emicizumab for acquired haemophilia A: A case series
42. The use of prothrombin complex concentrate in chronic liver disease: A review of the literature
43. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
44. Prevalence of COVID-19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: A survey from Europe
45. Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working Group
46. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
47. Prevalence of COVID‐19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: A survey from Europe
48. Discordance between joint pain and imagery severity in the ankle joint and contributors of lower limb activity limitations in adults with haemophilia: A cross‐sectional study
49. Pain interferes with daily activities, emotions and sleep in adults with severe, moderate and mild haemophilia: A national cross‐sectional survey
50. Successful in‐patient management of COVID‐19 infection in an old severe haemophilia A patient on emicizumab with multiple prothrombotic comorbidities
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.